作为肝纤维化生物标志物的血管紧张素转换酶血清水平

StephenW

World J Gastroenterol. 2017 Dec 28;23(48):8439-8442. doi: 10.3748/wjg.v23.i48.8439.
Serum levels of angiotensin converting enzyme as a biomarker of liver fibrosis.Miranda AS1, Simões E Silva AC2.
Author information
1Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG 30130-100, Brazil [email protected].2Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG 30130-100, Brazil.

AbstractThe renin angiotensin system (RAS) is classically conceived as a circulating hormonal system involved in blood pressure control and hydroelectrolyte balance. The discovery that RAS components are locally expressed in a wide range of organs and tissues, including the liver, pointed to a role for this system in the pathogenesis of several conditions including hepatic fibrosis and cirrhosis. It has been widely reported that the classical RAS axis composed by the angiotensin converting enzyme (ACE)-angiotensin (Ang) II-Ang type 1 (AT1) receptor mediates pro-inflammatory, pro-thrombotic, and pro-fibrotic processes. On the other hand, the alternative axis comprising ACE2-Ang-(1-7)-Mas receptor seems to play a protective role by frequently opposing Ang II action. Chronic hepatitis B (CHB) is one of the leading causes of liver fibrosis, accounting for the death of nearly one million people worldwide. Liver fibrosis is a key factor to determine therapeutic interventions for patients with CHB. However, the establishment of non-invasive and accurate methods to detect reversible stages of liver fibrosis is still a challenge. In an elegant study published in the 36th issue of the World Journal of Gastroenterology, Noguchi et al showed the predictive value of serum ACE levels in detecting not only advanced stages of liver fibrosis but also initial and intermediate fibrotic stages. The serum levels of ACE might represent an accurate, non-invasive, widely available, and easy method to evaluate fibrosis related to CHB. Moreover, therapies involving the inhibition of the classical RAS axis components might be promising in the control of CHB-related liver fibrosis.


KEYWORDS: Angiotensin II; Angiotensin converting enzyme; Angiotensin-(1-7); Chronic hepatitis B; Hepatic cirrhosis; Liver fibrosis; Renin angiotensin system

PMID:29358853PMCID:PMC5752705DOI:10.3748/wjg.v23.i48.8439

StephenW

世界J Gastroenterol。 2017年12月28日; 23（48）：8439-8442。 doi：10.3748 / wjg.v23.i48.8439。
作为肝纤维化生物标志物的血管紧张素转换酶血清水平。
Miranda AS1，SimõesE Silva AC2。
作者信息

1
    巴西米纳斯吉拉斯联邦大学医学院医学检查跨学科实验室，贝洛奥里藏特，MG 30130-100，巴西[email protected]。
2
    巴西米纳斯吉拉斯州联邦大学医学院医学检查跨学科实验室，贝洛奥里藏特，MG 30130-100，巴西。

抽象

肾素血管紧张素系统（RAS）通常被认为是一种参与血压控制和水电解质平衡的循环激素系统。 RAS组分在包括肝脏在内的多种器官和组织中局部表达的发现指示了该系统在包括肝纤维化和肝硬化在内的多种病症的发病机理中的作用。据报道，由血管紧张素转化酶（ACE） - 血管紧张素（Ang）II-Ang1型（AT1）受体组成的经典RAS轴介导促炎，促血栓形成和促纤维化过程。另一方面，包含ACE2-Ang-（1-7）-Mas受体的替代轴似乎通过经常反对Ang II的作用起到保护作用。慢性乙型肝炎（CHB）是肝纤维化的主要原因之一，占全世界近百万人的死亡。肝纤维化是确定慢性乙型肝炎患者治疗干预的关键因素。然而，建立非侵入性和准确的方法来检测肝纤维化的可逆阶段仍然是一个挑战。 Noguchi等在“世界胃肠病学杂志”第36期发表的一篇优雅的研究中显示，血清ACE水平在检测肝纤维化的晚期阶段以及初始和中期纤维化阶段的预测价值。 ACE的血清水平可能代表了一种准确的，非侵入性的，广泛可用的，容易评估与慢性乙型肝炎相关的纤维化的方法。此外，抑制经典RAS轴成分的治疗在CHB相关肝纤维化的控制中可能是有希望的。
关键词：

血管紧张素II;血管紧张素转换酶;血管紧张素 - （1-7）;慢性乙型肝炎;肝硬化;肝纤维化;肾素血管紧张素系统

结论：
    29358853
PMCID：
    PMC5752705
DOI：
    10.3748 / wjg.v23.i48.8439